Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 426 - 450 of 646 in total
Bamocaftor (VX-659) is under investigation in clinical trial NCT03224351 (A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis).
Investigational
Matched Salts name: … Bamocaftor potassium
A P2Y12 inhibitor and platelet aggregation inhibitor.
Investigational
Matched Salts name: … Elinogrel potassium
Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan. It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism .
Experimental
Matched Salts name: … Saprisartan potassium
Vaniprevir has been used in trials studying the treatment and diagnostic of Hepatitis C, Chronic Hepatitis C, Hepatitis C, Chronic, Chronic Hepatitis C Infection, and Chronic Genotype 1 Hepatitis C Virus Infection.
Investigational
Matched Salts name: … Vaniprevir potassium
Experimental
Matched Categories: … Sodium-Potassium-Exchanging ATPase, antagonists & inhibitors …
Experimental
Experimental
Volixibat, also known as SHP626 or LUM002, is an investigational drug that will potentially be used for the treatment of Non-Alcoholic Steatohepatitis (NASH). If approved for use, it will be the first available agent for the treatment of NASH. Volixibat is a selective inhibitor of the apical sodium-dependent bile acid...
Experimental
Investigational
Matched Salts name: … Volixibat potassium
Experimental
Experimental
Experimental
Displaying drugs 426 - 450 of 646 in total